Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
Crossref DOI link: https://doi.org/10.1007/s00296-015-3374-2
Published Online: 2015-10-22
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cárdenas, M.
de la Fuente, S.
Font, P.
Castro-Villegas, M. C.
Romero-Gómez, M.
Ruiz-Vílchez, D.
Calvo-Gutiérez, J.
Escudero-Contreras, A.
Casado, M. A.
Del Prado, J. R.
Collantes-Estévez, E.
Text and Data Mining valid from 2015-10-22